



Accomplishments Report: 2024

Advancing innovation to save lives

January 2025

INTRODUCTION

The Global Health Technologies Coalition (GHTC) is committed to advancing policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people worldwide. We advocate for the US government and multilateral entities to enact policies and commit resources to catalyze the development of new technologies to address the world's most pressing health challenges. This report summarizes the coalition's impact and collective efforts in 2024.

ACCOMPLISHMENTS

Protected and expanded funding for global health R&D

Our win: Influenced Congress to [increase or largely maintain funding](#) for global health R&D-relevant accounts in the fiscal year 2024 budget, despite a challenging fiscal climate.

What it took: This took sustained advocacy, starting in 2023. In addition to increasing funding for the Biomedical Advanced Research and Development Authority (BARDA) and the US Centers for Disease Control and Prevention (CDC) National Center for Emerging and Zoonotic Infectious Diseases and protecting funding for the Coalition for Epidemic Preparedness Innovations (despite cuts to global health security funding), the funding package also included important report language supported by GHTC, including directives for the US Agency for International Development (USAID) to increase its health R&D spending and BARDA to spend \$10 million on a Disease X program. To influence the yet-to-be-passed fiscal year 2025 budget, GHTC last year conveyed [testimony](#) and [letters](#), positioned questions and talking points for congressional hearings, submitted 264 report language requests to 47 congressional offices, and met with 18 offices to reinforce our asks.



GHTC staff and member representatives on Capitol Hill for the coalition's annual appropriations Hill Day.

Advanced SIGHT Act and other legislative and US agency efforts

Our win: Advanced Senate [introduction](#) of the [SIGHT Act](#) and secured [five additional cosponsors](#) for the House version, as well as supported other legislative and agency efforts.

What it took: GHTC met with at least 22 congressional offices on the Supporting Innovative Global Health Technologies (SIGHT) Act and advanced a House Dear Colleague letter to increase political support for the legislation, as well as liaised between key staff from USAID and bill sponsors to address USAID technical assistance and questions. GHTC also secured [report language](#) in the Senate fiscal year 2025 State, Foreign Operations, and Related Programs appropriations bill report directing USAID to explore the feasibility of creating a dedicated health R&D funding line, a signal of support and a step toward realizing the SIGHT Act, which we hope will be carried over in the final appropriations package passed in 2025. In addition to advocating for the SIGHT Act, GHTC also contributed to efforts to advance the [End Tuberculosis Now Act](#), which passed the Senate; the [Pioneering Antibiotic Subscription to End Upsurging Resistance Act](#); and [reauthorization](#) of the Pandemic and All-Hazards Preparedness and Innovation Act and responded to requests for information on the [House's](#) National Institutes of Health [reorganization/reform proposal](#), the [Next Generation Cures Act](#), the National Institute of Allergy and Infectious Diseases' [strategic plan](#), and USAID's global health development policy. For the first time in half a decade, the Department of Health and Human Services also updated its [global strategy](#), which includes a much stronger focus on global health R&D, reflecting sustained engagement by GHTC over the past few years.

2024 by the numbers



5

policies adopted



1

GHTC-led bill introduced



7

new coalition members



104

congressional meetings



91

meetings with US & multilateral officials



16

educational & advocacy resources created



264

US appropriations report language requests submitted



53

pieces of evidence provided to policymakers & influencers



64

blog posts, including 50 weekly R&D news roundups & 14 original pieces



3

members of Congress honored

Generated compelling evidence to buttress our US advocacy

Our win: Generated compelling new evidence on the return on investment of US government global health R&D funding at the global, national, and state levels to buttress our US advocacy.



What it took: It took significant behind-the-scenes work by our partner, Impact Global Health (formerly Policy Cures Research), and GHTC on our [Doing Well by Doing Good](#) report, which analyzed trends in US government investment and the returns from it, and GHTC's companion [state-level analysis](#) detailing the economic returns in each state. These analyses were covered by [media outlets](#) and showcased at a Capitol Hill event, which featured remarks from Representatives Mike Levin (D-CA) and Ami Bera (C-CA). In addition to launching these analyses, GHTC also updated a [six-part fact sheet series](#) on how various US agencies contribute to global health R&D and a [seven-part series on how R&D](#) is driving progress in different global health areas.

Influenced new WHO clinical trial guidance


Our win: [Influenced the release](#) by the World Health Organization (WHO) of [new guidance](#) on best practices in clinical trials, which includes a focus on strengthening trial infrastructure globally and expanding the inclusion of underrepresented populations in clinical research.

What it took: This was a result of a multiyear advocacy effort by GHTC and partners, which included advancing the adoption and [implementation](#) of the 2022 World Health Assembly (WHA) [resolution](#) on strengthening clinical trials and providing [direct technical input](#) on the guidance via public consultations and meetings with WHO decision-makers.

Secure important reforms to WHO PQ program

Our win: Helped advance two important reforms to WHO's Prequalification (PQ) program to reduce bottlenecks and improve transparency: the launch of a new [online PQ application portal](#) and the introduction of a new [process](#) for developing guidelines for the use of novel products in parallel with certifying their safety and efficacy via PQ and emergency use listing assessment.

What it took: These wins came after a two-year advocacy effort kicked off in 2022 with the launch of a GHTC coauthored [report with recommendations to strengthen PQ followed](#) by a series of events and interventions elevating the issue at fora like WHA and the [WHO Executive Board \(EB\) meeting](#), a [commentary blog](#), and direct meetings with WHO officials and staff. This past fall, GHTC also launched a new [PQ scorecard](#) to illuminate improvements and remaining gaps in the availability of information on PQ's website to drive the next phase of our advocacy.



Informed adoption of IHR amendings, including new R&D provisions

Our win: Informed the [adoption](#) of a package of [amendments](#) to the International Health Regulations (IHR), which include new R&D-relevant provisions directing parties, as appropriate, to support coordinating mechanisms for R&D and efforts to diversify the geographic production of health products.

What it took: To push for greater inclusion of R&D in both the IHR amendment package and the pandemic accord negotiations, GHTC participated in numerous civil society forums and informal consultations with WHO and other key decision-makers. GHTC also provided direct [written input](#) to the [US government](#) and delivered statements to key decision-makers during official civil society consultative sessions.

Advanced WHA resolutions to further R&D

Our win: Advanced the adoption by the [77th WHA](#) of resolutions on [antimicrobial resistance \(AMR\)](#) and [maternal, newborn, and child health](#), which featured R&D-relevant provisions—with the former calling on member states to support R&D to combat AMR and the latter emphasizing the importance of advancing medicines for pediatric populations and pregnant and lactating women.



GHTC's Executive Director and Senior Multilateral Policy and Advocacy officer at WHA; CDC Director Mandy Cohen speaks at GHTC event.

What it took: To help [advance](#) these outcomes, GHTC worked with the Global Health Council (GHC) to shape statements on AMR delivered at the [EB Meeting](#) and [WHA](#), [urged](#) support for these efforts from the US delegation, and cohosted with GHC an executive roundtable focused on AMR on the sidelines of WHA.

Shaped political commitments for R&D via AMR HLM and G7/G20

Our win: Influenced the [adoption](#) of a political declaration at the [United Nations High-Level Meeting \(HLM\) on AMR](#) and outcome declarations at the [G20 Health Ministers' Meeting](#) and [G7 Leaders' and Health Ministers' Meetings](#), which included commitments to health R&D, including, for the G20, the establishment of a new [coalition](#) to promote local and regional production of health products for neglected diseases.

What it took: This took sustained advocacy efforts to elevate [R&D-specific priorities](#) and [reports](#) from partner advocacy organizations, including the [G20 and G7 Health and Development Partnership](#), InterAction, and the International Pandemic Preparedness Secretariat, as well as direct GHTC engagement with the AMR HLM facilitators, US government sherpas and [global affairs](#) and national security leads, and representatives of the Brazilian government, which held the G20 presidency.

Strengthened our bench of champions

Our win: Continued to develop and strengthen relationships with congressional, US agency, and multilateral decision-makers.



What it took: Last year GHTC met with 48 congressional offices to further our advocacy objectives and held our annual [Innovating for Impact Awards](#) event, at which we honored Senators Susan Collins (R-ME) and Cory Booker (D-NJ), Representative Chrissy Houlahan (D-PA), and the partners who advanced the novel oral polio vaccine type 2. On the agency front, we cohosted a town hall with USAID Assistant Administrator for Global Health Dr. Atul Gawande, held regular Friends of CDC Global briefings with key agency staff, and engaged directly with more than 60 agency and multilateral officials.

Grew GHTC membership

Our win: GHTC gained seven new member organizations, including the [American Society for Microbiology](#), [Blueprint Biosecurity](#), [FHI 360](#), the [Centre for Infectious Disease Research in Zambia](#), the [Bay Area Global Health Alliance](#), [Vizuri Health Dynamics](#), and [Health 4 Development](#).

What it took: A track record of past impact and leveraging opportunities to network with stakeholders in the global health and R&D sectors.



Front page cover photo credits (from left to right, top to bottom): Architect of the Capitol; WHO/Pierre Albouy; PATH/Georgina Goodwin.



The Global Health Technologies Coalition (GHTC) works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 45 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

www.ghtcoalition.org

January 2025